Research progress on the mechanism of β-lactam resistance in group A Streptococci in vivo
10.7499/j.issn.1008-8830.2306157
- VernacularTitle:A族链球菌体内耐受β-内酰胺类药物的机制研究进展
- Author:
Meng-Yang GUO
1
;
Kai-Hu YAO
Author Information
1. 国家儿童医学中心/首都医科大学附属北京儿童医院/北京市儿科研究所微生物研究室/国家呼吸系统疾病临床医学研究中心/教育部儿科重大疾病研究重点实验室,北京 100045
- Keywords:
Group A Streptococcus;
Streptococcus pyogenes;
Penicillin;
β-lactam;
Treatment failure
- From:
Chinese Journal of Contemporary Pediatrics
2024;26(1):92-97
- CountryChina
- Language:Chinese
-
Abstract:
β-lactams,including penicillin,have been used for over 80 years in the treatment of group A Streptococcus(GAS)infections.Although β-lactam-resistant GAS strains have not been identified in vitro tests,clinical treatment failures have been reported since the 1950s.The mechanism underlying the clinical failure of β-lactam treatment in GAS infections remains unclear.Previous research has suggested that β-lactam resistance in GAS in vivo is associated with reduced drug susceptibility of strains,bacterial inoculation effects,biofilm formation,the effect of coexisting bacteria,bacterial persistence,and bacterial internalization into host cells.This article reviews the main reports on β-lactam treatment failure in GAS infections and analyzes the possible mechanisms of β-lactam resistance in vivo.The findings aim to contribute to future research and clinical approaches in the field.
